Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Granulocytic myeloid-derived suppressor cells in MM

Bruno Paiva • 15 May 2020
COMy Virtual 2020
Multiple Myeloma

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, talks on the immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruno Paiva

MRD assessment as an early endpoint of treatment efficacy in AML: a PETHEMA registry study
2:22
MRD assessment as an early endpoint of treatment efficacy in AML: a PETHEMA registry study
Bruno Paiva • 6 Dec 2025
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
2:25
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
Bruno Paiva • 6 Dec 2025
Comprehensive genomic characterization of CTCs in multiple myeloma
1:38
Comprehensive genomic characterization of CTCs in multiple myeloma
Bruno Paiva • 6 Dec 2025
What is the most effective method for detecting circulating tumor cells in multiple myeloma?
1:40
What is the most effective method for detecting circulating tumor cells in multiple myeloma?
Bruno Paiva • 18 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Bruno Paiva • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Bruno Paiva • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Bruno Paiva • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Bruno Paiva • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals